Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC decreased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 36.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,932 shares of the company’s stock after selling 5,190 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Henry Schein were worth $651,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Livforsakringsbolaget Skandia Omsesidigt grew its position in Henry Schein by 282.1% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,490 shares of the company’s stock valued at $109,000 after acquiring an additional 1,100 shares in the last quarter. GAMMA Investing LLC grew its position in Henry Schein by 106.7% in the third quarter. GAMMA Investing LLC now owns 2,069 shares of the company’s stock valued at $151,000 after acquiring an additional 1,068 shares in the last quarter. Czech National Bank grew its position in Henry Schein by 5.8% in the third quarter. Czech National Bank now owns 25,811 shares of the company’s stock valued at $1,882,000 after acquiring an additional 1,409 shares in the last quarter. Handelsbanken Fonder AB grew its position in shares of Henry Schein by 41.9% during the third quarter. Handelsbanken Fonder AB now owns 34,900 shares of the company’s stock worth $2,544,000 after buying an additional 10,300 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Henry Schein by 1,622.3% during the third quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock worth $33,449,000 after buying an additional 432,187 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the sale, the senior vice president now directly owns 71,833 shares in the company, valued at approximately $4,978,026.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.14% of the stock is currently owned by company insiders.

Henry Schein Stock Performance

Shares of HSIC opened at $72.39 on Friday. The business’s fifty day moving average price is $70.33 and its 200 day moving average price is $69.91. Henry Schein, Inc. has a 12-month low of $60.01 and a 12-month high of $82.63. The stock has a market capitalization of $9.27 billion, a PE ratio of 24.26, a price-to-earnings-growth ratio of 1.98 and a beta of 0.86. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.55 and a quick ratio of 0.90.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. The company had revenue of $3.10 billion for the quarter, compared to analysts’ expectations of $3.27 billion. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the business posted $1.31 earnings per share. Equities research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on HSIC. Evercore ISI raised their price target on shares of Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 8th. Baird R W raised shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 22nd. JPMorgan Chase & Co. decreased their price target on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Robert W. Baird decreased their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Finally, UBS Group decreased their price target on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Henry Schein has a consensus rating of “Hold” and an average target price of $77.50.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.